ABC  Vol.5 No.5 , August 2015
Glycation Induced Physicochemical Changes in Low-Density Lipoprotein and Its Role in Promoting Cholesterol Accumulation in Macrophages along with Antiglycation Effect of Aminoguanidine
ABSTRACT
The present study aimed at investigating physicochemical changes in modified LDL by sugars specifically fructose due to recent reports on its involvement in cardiovascular diseases and also glucose and their role in subsequent in vitro accumulation of cholesterol in macrophages. Antiglycation action of aminoguanidine was also investigated. LDL isolated from human blood was incubated with fructose or glucose and aminoguanidine where indicated. The physicochemical changes in modified LDL were detected by electrophoretic, spectroscopic and chemical analysis. Accumulation of cholesterol and its inhibiton in human monocyte-derived macrophages incubated with modified LDL was determined by HPLC. Results showed increased relative electrophoretic mobility, hyperchromicity at 280 nm, development of AGE fluorescence, decrease in free amino groups and increased carbonyl content in glycated LDL as compared to native LDL. Also total cholesterol accumulated in macrophages was more for glycated LDL as compared to native LDL. The magnitude of changes was more prominent in case of fructose as compared to glucose. Aminoguanidine showed remarkable restriction of glycation-induced alterations in LDL and also in accumulation of cholesterol in macrophages. The study thus proclaims that LDL-AGEs formed by fructose may contribute to accelerated initiation of diabetes induced atherosclerosis via foam cells generation and aminoguanidine may have therapeutic potential against it.

Cite this paper
Jairajpuri, D. , Fatima, S. and Jairajpuri, Z. (2015) Glycation Induced Physicochemical Changes in Low-Density Lipoprotein and Its Role in Promoting Cholesterol Accumulation in Macrophages along with Antiglycation Effect of Aminoguanidine. Advances in Biological Chemistry, 5, 203-214. doi: 10.4236/abc.2015.55017.
References
[1]   Cerami, A. and Ulrich, P. (2001) Pharmaceutical Intervention of Advanced Glycation Endproducts. Novartis Foundation Symposia, 235, 202-212.

[2]   Anguizola, J., Matsuda, R., Barnaby, O.S., Hoy, K.S., Wa, C.L., DeBolt, E., Koke, M. and Hage, D.S. (2013) Review: Glycation of Human Serum Albumin. Clinica Chimica Acta, 425, 64-76.
http://dx.doi.org/10.1016/j.cca.2013.07.013

[3]   Yokoyama, H., Araki, S., Haneda, M., Matsushima, M., Kawai, K., Hirao, K., Oishi, M., Sugimoto, K., Sone, H., Maegawa, H. and Kashiwagi, A. (2012) Chronic Kidney Disease Categories and Renal-Cardiovascular Outcomes in Type 2 Diabetes without Prevalent Cardiovascular Disease: A Prospective Cohort Study (JDDM25). Diabetologia, 55, 1911-1918.
http://dx.doi.org/10.1007/s00125-012-2536-y

[4]   Yamagishi, S., Nakamura, K. and Matsui, T. (2006) Advanced Glycation End Products (AGEs) and Their Receptor (RAGE) System in Diabetic Retinopathy. Current Drug Discovery Technologies, 3, 83-88.
http://dx.doi.org/10.2174/157016306776637555

[5]   Ghosh-Moulick, R., Bhattacharya, J., Roy, S., Basak, S. and Dasgupta, A.K. (2007) Compensatory Secondary Structure Alterations in Protein Glycation. Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics, 1774, 233-242.
http://dx.doi.org/10.1016/j.bbapap.2006.11.018

[6]   Sakai, M., Oumomi, M. and Kasuga, M. (2002) Experimental Studies on the Role of Fructose in the Development of Diabetic Complications. Kobe Journal of Medical Sciences, 48, 125-136.

[7]   Poulsom, R., Boot-Handford, R.P. and Heath, H. (1983) The Effects of Long-Term Treatment of Streptozotocin-Diabetic Rats with an Aldose Reductase Inhibitor. Experimental Eye Research, 37, 507-515.
http://dx.doi.org/10.1016/0014-4835(83)90027-1

[8]   Gasser, A. and Forbes, J.M. (2008) Advanced Glycation: Implications in Tissue Damage and Disease. Protein and Peptide Letters, 15, 385-391.
http://dx.doi.org/10.2174/092986608784246515

[9]   Stitt, A.W. (2003) The Role of Advanced Glycation in the Path-ogenesis of Diabetic Retinopathy. Experimental and Molecular Pathology, 75, 95-108.
http://dx.doi.org/10.1016/S0014-4800(03)00035-2

[10]   Rashid, I., Brown, B.E., van Reyk, D.M. and Davies, M.J. (2006) The Roles of Glycation, Glycoxidation and Advanced Glycation End-Product Formation in Diabetes-Induced Ather-osclerosis. In: Cheema, S.K., Ed., Biochemistry of Artherosclerosis, Springer Verlag, New York, 247-283.
http://dx.doi.org/10.1007/0-387-36279-3_12

[11]   Zimmermann, R., Panzenbock, U., Wintersperger, A., Levak-Frank, S., Graier, W., Glatter, O., Fritz, G., Kostner, G.M. and Zechner, R. (2001) Lipoprotein Lipase Mediates the Uptake of Glycated LDL in Fibroblasts, Endothelial Cells, and Macrophages. Diabetes, 50, 1643-1653.
http://dx.doi.org/10.2337/diabetes.50.7.1643

[12]   Lyons, T.J. (1993) Glycation and Oxidation: A Role in the Patho-genesis of Atherosclerosis. American Journal of Cardiology, 71, 26-31.
http://dx.doi.org/10.1016/0002-9149(93)90142-Y

[13]   Majd, A.A., Goodarzi, M.T., Hassanzadeh, T., Tavilani, H. and Karimi, J. (2014) Aminoguanidine Partially Prevents the Reduction in Liver Pyruvate Kinase Activity in Diabetic Rats. Advances in Biomedical Research, 3, 260-265.
http://dx.doi.org/10.4103/2277-9175.148233

[14]   Panagiotopoulos, S., Brien, R.C.O., Bucala, R., Cooper, M.E. and Jerums, G. (1998) Aminoguanidine Has an Anti-Atherogenic Effect in the Cholesterol-Fed Rabbit. Atherosclerosis, 136, 125-131.
http://dx.doi.org/10.1016/S0021-9150(97)00192-5

[15]   Rabbani, N., Chittari, M.V., Bodmer, C.W., Zehnder, D., Ceriello, A. and Thornalley, P.J. (2010) Increased Glycation and Oxidative Damage to Apolipoprotein B100 of LDL Cholesterol in Patients with Type 2 Diabetes and Effect of Metformin. Diabetes, 59, 1038-1045.
http://dx.doi.org/10.2337/db09-1455

[16]   Ahmad, S., Akhter, F., Moinuddin, Shahab, U. and Khan, M.S. (2013) Studies on Glycation of Human Low Density Lipoprotein: A Functional Insight into Physic-Chemical Analysis. International Journal of Biological Biomolecules, 62, 167-171.

[17]   Rashid, I., van Reyk, D.M. and Davies, M.J. (2007) Carnosine and Its Constituents Inhibit Glycation of Low-Density Lipoproteins That Promotes Foam Cell Formation in Vitro. FEBS Letters, 581, 1067-1070.
http://dx.doi.org/10.1016/j.febslet.2007.01.082

[18]   Brown, B.E., Dean, R.T. and Davies, M.J. (2005) Glycation of Low-Density Lipoproteins by Methylglyoxal and Glycoaldehyde Gives Rise to the in Vitro Formation of Lipid-Laden Cells. Diabetologia, 48, 361-369.
http://dx.doi.org/10.1007/s00125-004-1648-4

[19]   Younis, N.N., Soran, H., Pemberton, P., Charlton-Menys, V., Elseweidy, M.M. and Durrington, P.N. (2013) Small Dense LDL Is More Susceptible to Glycation than More Buoyant LDL in Type 2 Diabetes. Clinical Science (London), 124, 343-349.
http://dx.doi.org/10.1042/CS20120304

[20]   Garner, B., Dean, R.T. and Jessup, W. (1994) Human Macro-phage-Mediated Oxidation of Low-Density Lipoprotein Is Delayed and Independent of Superoxide Production. Journal of Biochemistry, 301, 421-428.

[21]   Habeeb, A.F.S.A. and Hiramoto, R. (1968) Reaction of Proteins with Glutaraldehyde. Archives of Biochemistry and Biophysics, 126, 16-26.
http://dx.doi.org/10.1016/0003-9861(68)90554-7

[22]   Levine, R.L., Williams, J., Stadtman, E.R. and Shacter, E. (1994) Carbonyl Assays for Determination of Oxidatively Modified Proteins. Methods in Enzymology, 233, 346-357.
http://dx.doi.org/10.1016/S0076-6879(94)33040-9

[23]   Brown, B.E., Mahroof, F.M., Cook, N.L., van Reyk, D.M. and Davies, M.J. (2006) Hydrazine Compounds Inhibit Glycation of Low-Density Lipo-proteins and Prevent the in Vitro Formation of Model Foam Cells from Glycolaldehyde-Modified Low-Density Lipoproteins. Diabetologia, 49, 775-783.
http://dx.doi.org/10.1007/s00125-006-0137-3

[24]   Jairajpuri, D.S., Fatima, S. and Saleemuddin, M. (2008) Complexing of Glucose Oxidase with Anti-Glucose Oxidase Antibodies or the F(ab)’2/F(ab)’ Fragments Derived There from Protects Both the Enzyme and Antibody/Antibody Fragments. Biochemistry, 73, 1235-1241.
http://dx.doi.org/10.1134/S0006297908110102

[25]   Labieniec-Watala, M., Siewiera, K. and Jozwiak, Z. (2011) Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes. International Journal of Molecular Sciences, 12, 8013-8026.
http://dx.doi.org/10.3390/ijms12118013

[26]   Price, D.L., Rhett, P.M., Thorpe, S.R. and Baynes, J.W. (2001) Chelating Activity of Advanced Glycation End-Product Inhibitors. Journal of Biological Chemistry, 276, 48967-48972.
http://dx.doi.org/10.1074/jbc.M108196200

[27]   Bachetti, T., Masciangelo, S., Armeni, T., Bicchiega, V. and Ferretti, G. (2014) Glycation of High Density Lipoprotein by Methylglyoxal: Effect on HDL-Paraoxonase Activity. Metabolism, 63, 307-311.
http://dx.doi.org/10.1016/j.metabol.2013.10.013

[28]   Koh, G., Lee, D. and Woo, J. (2010) 2-Deoxy-D-Ribose Induces Cellular Damage by Increasing Oxidative Stress and Protein Glycation in a Pancreatic Beta-Cell Line. Metabolism—Clinical and Experimental, 59, 325-332.
http://dx.doi.org/10.1016/j.metabol.2009.07.028

[29]   Thornalley, P.J. (2003) Use of Aminoguanidine (Pimagedine) to Prevent the Formation of Advanced Glycation Endproducts. Archives of Biochemistry and Biophysics, 419, 31-40.
http://dx.doi.org/10.1016/j.abb.2003.08.013

[30]   Ansari, N.A., Moinuddin, A.K. and Ali, A. (2009) Preferential Recognition of Amadori-Rich Lysine Residues by Serum Antibodies in Diabetes Mellitus: Role of Protein Glycation in the Disease Process. Human Immunology, 70, 417-424.
http://dx.doi.org/10.1016/j.humimm.2009.03.015

[31]   Jakus, V. and Rietbrock, N. (2004) Advanced Glycation End-Products and the Progress of Diabetic Vascular Complications. Physiological Research, 53, 131-142.

[32]   Lapolla, A., Molin, L. and Traldi, P. (2013) Protein Glycation in Diabetes as Determined by Mass Spectrometry. International Journal of Endocrinology, 2013, 1-11.
http://dx.doi.org/10.1155/2013/412103

[33]   Beal, M.F. (2002) Oxidatively Modified Proteins in Aging and Disease. Free Radical Biology and Medicine, 32, 797- 803.
http://dx.doi.org/10.1016/S0891-5849(02)00780-3

[34]   Li, A.C. and Glass, C.K. (2002) The Macrophage Foam Cell as a Target for Therapeutic Intervention. Nature Medicine, 8, 1235-1242.
http://dx.doi.org/10.1038/nm1102-1235

[35]   Zhang, Y.H., An, T., Zhang, R.C., Zhou, Q., Huang, Y. and Zhang, J. (2013) Very High Fructose Intake Increases Serum LDL-Cholesterol and Total Cholesterol: A Meta-Analysis of Controlled Feeding Trials. Journal of Nutrition, 143, 1391-1398.
http://dx.doi.org/10.3945/jn.113.175323

[36]   Bray, G.A., Nielsen, S.J. and Popkin, B.M. (2004) Consumption of High-Fructose Corn Syrup in Beverages May Play a Role in the Epidemic of Obesity. American Journal of Clinical Nutrition, 79, 537-543.

[37]   Aeberli, I., Zimmermann, M.B., Molinari, L., Lehmann, R., L’Allemand, D., Spinas, G.A. and Berneis, K. (2007) Fructose Intake Is a Predictor of LDL Particle Size in Overweight Schoolchildren. American Journal of Clinical Nutrition, 86, 1174-1178.

[38]   Miyazawa, N., Kawasaki, Y. and Fuji, J. (1998) Immunological Detection of Fructated Proteins in Vivo and in Vitro. Biochemistry Journal, 336, 101-107.

[39]   Bantle, J.P., Raatz, S.K., Thomas, W. and Georgopoulos, A. (2000) Effects of Dietary Fructose on Plasma Lipids in Healthy Subjects. American Journal of Clinical Nutrition, 72, 1128-1134.

 
 
Top